HEB



JOHP

JOHP-ISSN: 2348-7704

Journal of Hospital Pharmacy

An Official Publication of Bureau for Health & Education Status Upliftment

(Constitutionally Entitled as Health-Education, Bureau)

Onset of Systemic Lupus Erythematosus Followed By Covid 19 Infection - A First Case Report From India

Nithya R*¹, Anjuna Prakashan², P.Sharmila Nirojini³, P.NithyaKala⁴, Anjana E⁵

- *1,4Assistant professor, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam-637205, Namakkal Dist, Tamilnadu, India
- ²Assistant professor, Department of Pharmaceutics, Swamy Vivekanandha College of Pharmacy, Elayampalayam-637205, Namakkal Dist, Tamilnadu, India
- ³Head of the department, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam-637205, Namakkal Dist, Tamilnadu, India
- ⁵Assistant professor, Department of Pharmaceutical Analysis, Swamy Vivekanandha College of Pharmacy, Elayampalayam-637205, Namakkal Dist, Tamilnadu, India

Corresponding Author

Nithya R, Assistant Professor, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Elayampalayam-637205, Namakkal Dist, Tamilnadu, INDIA

Email Id: serviceheb@gmail.com

ABSTRACT

We present a case report of 49 year old female of Indian origin diagnosed with SLE followed by COVID 19 infection. After 58 days Post COVID 19 infection the patient presented with symptoms of generalized body pain, arthralgia, Anaemia for the past 2 weeks and was taking methylprednisolone 200mg. Her lab investigations show huge abnormality in Hb levels, Haemolytic anaemia was confirmed with peripheral smear analysis. Anti Nuclear Antibody (ANA), Anti double stranded Deoxyribo Nucleic Acid (Anti ds DNA) positive confirms SLE in this patient, the patient was treated with Injection (Inj) Rituximab 500mg Intravenously (IV) for 4 weeks, paracetamol 650mg, Inj Avil 1amp, Inj Hydrocortisone ampoule IV. Condition seems to be improved in patient. During her 2nd review 2nd dose of Rituximab 500mg was administered, after 3months of follow up patient reported with Protein loss and currently treated with

Telmisartan 40mg. This is the first case study to be reported from India. Regular monitoring and prior immunological and clinical follow up are needed for post-COVID 19 patients. The goal of this case study is to make aware the health care professionals regarding the condition of SLE followed by COVID 19 Infection. *Keywords:* COVID 19, Systemic Lupus Erythematosus, Anaemia, Anti Nuclear Antibody, Rituximab.

| Access | this | Article | Online |
|--------|------|---------|--------|
| | | | |

Website: http://www.journalofhospitalpharmacy.in

Received on 30/01/2022

Accepted on 12/02/2022 © HEB All rights reserved

